TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10765004
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of octreotide (50 microg every 6 hours) plus intravenous infusion of low-dose insulin (4 units per hour)
Study: 10765004
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin alone (4 units per hour)
Study: 1835291
Drug: Theophylline (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (dose titrated to produce serum levels of 10-20 micrograms/mL)
Study: 24728028
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy (IFC)
Study: 16603634
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg intravenously at weeks 0 and 4
Study: 16603634
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg intravenously at weeks 0, 2, 4, and 6
Study: 3896811
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg I.V. followed by oral administration)
Study: 22835702
Drug: Synbiotic food
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic food supplement (containing fructo‐oligosaccharides and probiotic strains)
Study: 22835702
Drug: Synbiotic food
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic food supplement
Study: 21055143
Drug: Thymopetide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopetide (2 mg/day i.m. for 75 days)
Study: 15993253
Drug: SSRI antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressants (specific SSRIs not detailed)
Study: 15993253
Drug: Discontinued SSRI
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued SSRI treatment
Study: 15993253
Drug: Baseline patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline patient skepticism about taking an antidepressant
Study: 10801969
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose zinc supplements
Study: 10801969
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antioxidants
Study: 8719121
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BL) at 3000 lux for 6 days after PSD
Study: 8719121
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light therapy (DL) at 100 lux for 6 days after PSD
Study: 1595849
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg pretreatment
Study: 25234807
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy (1200 mg per day for 4-6 weeks, then 300-600 mg per day)
Study: 25234807
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard chemotherapy regimen)
Study: 17285968
Drug: Endonasal sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months plus injection of beclomethasone (Group 2)
Study: 29635395
Drug: Accelerated Resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Resolution Therapy (ART); mean number of sessions received: 3.9 ± 1.1.
Study: 25676540
Drug: Oral Δ(9)‐THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Δ(9)‐THC (maximum 28 mg/day)
Study: 21917649
Drug: Celecoxib treatment
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib treatment for 24 months
Study: 21917649
Drug: Anti-H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H pylori treatment for 7 days
Study: 19687005
Drug: Telemonitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring with pharmacological treatment for 6 months
Study: 19687005
Drug: Telemonitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring with pharmacological treatment for 6 months (per-protocol analysis)
Study: 15286098
Drug: Ximelagatran 36
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 36 mg twice daily for 8 days
Study: 15286098
Drug: Digoxin 0.5
Normalized name: digoxin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.5 mg single oral dose on day 4
Study: 9701198
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg riboflavin daily for 12 weeks
Study: 9701198
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg riboflavin daily for 12 weeks
Study: 8611450
Drug: Campath‐1H (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath‐1H (humanized CD52 monoclonal antibody)
Study: 2285631
Drug: Propionyl carnitine
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl carnitine (PC) 500 mg three times a day for 30 days
Study: 21273492
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration during meal
Study: 21273492
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration during OGTT
Study: 21273492
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration during hyperglycemic clamps
Study: 21273492
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration after improved glycemic control
Study: 20112480
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus music therapy (Group Acup. + M)
Study: 16636212
Drug: Calcium carbonate,
Normalized name: calcium carbonate, precipitated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbonate, 600 mg twice per day
Study: 11591548
Drug: Dextromethorphan hydrobromide,
Normalized name: Dextromethorphan Hydrobromide, 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide, 30 mg
Study: 9334894
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg for > or = 7 weeks
Study: 8228350
Drug: Single-dose live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose live oral cholera vaccine strain CVD 103-HgR (5 x 10(9) cfu)
Study: 8228350
Drug: Single-dose live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose live oral cholera vaccine strain CVD 103-HgR
Study: 10421260
Drug: Postoperative intrahepatic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intrahepatic arterial chemotherapy (2-3 courses with a maximum dose of 80 mg of cisplatin and 10 mg of mitomycin C at 1-month intervals)
Study: 7570405
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled steroid (400 micrograms beclomethasone dipropionate) + salmeterol (100 micrograms)
Study: 7570405
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled steroid (1000 micrograms beclomethasone dipropionate)
Study: 6182894
Drug: Lidocaine (trimecain)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (trimecain) administered intravenously and then intramuscularly for a day
Study: 6182894
Drug: Lidocaine administered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administered intramuscularly for 1.8 years
Study: 23392332
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg i.v. (dexamethasone group, n = 20)
Study: 19927630
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus irbesartan (150 mg/d)
Study: 17530099
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose E2/NETA (2 mg E2/1 mg NETA)
Study: 15167457
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lisinopril (LIS) daily for 4 weeks
Study: 15167457
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide (HCT) daily for 4 weeks
Study: 31397488
Drug: telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine 600 mg/d oral
Study: 31397488
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiviral drugs)
Study: 26216500
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (40-60 mg/day)
Study: 26216500
Drug: Intramuscular adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular adrenocorticotropic hormone (40-60 IU/every other day)
Study: 23137389
Drug: Oral altrenogest
Normalized name: Altrenogest
DrugBank: Altrenogest (DB11372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral altrenogest (0.044 mg/kg; Regumate(®) ) for 11 days
Study: 23137389
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone (1.38 g; CIDR(®) ) for 11 days
Study: 11032589
Drug: Toremifene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 40 mg/d
Study: 11032589
Drug: Toremifene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 40 mg/d (ER-positive subgroup)
Study: 11032589
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d (ER-positive subgroup)
Study: 1740538
Drug: HCTZ/TRI (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ/TRI (25 mg/50 mg)
Study: 1740538
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg (Ate-25)
Study: 1740538
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (Ate-50)
Study: 1740538
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg + HCTZ/TRI (Ate-25/HCTZ/TRI)
Study: 1740538
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg + HCTZ/TRI (Ate-50/HCTZ/TRI)
Study: 1740538
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg (Ate-25), Atenolol 50 mg (Ate-50), HCTZ/TRI, Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Study: 1740538
Drug: HCTZ/TRI (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ/TRI (25 mg/50 mg), Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Study: 6747020
Drug: experimental extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental extended‐release capsules
Study: 6747020
Drug: experimental extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental extended‐release tablets
Study: 31022213
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40 IU once daily for four weeks)
Study: 31022213
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline once daily for four weeks)
Study: 15860827
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral supplementation using 1000 mg calcium with 800 IU cholecalciferol and information leaflet on dietary calcium intake and prevention of falls
Study: 8017639
Drug: AVP type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP type V1 antagonist (AVPA)
Study: 8017639
Drug: Enalapril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1.25 mg intravenous)
Study: 8017639
Drug: Enalapril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1.25 mg intravenous) + AVPA (0.5 mg)
Study: 8017639
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine (control)
Study: 1066224
Drug: Local anesthetics
Normalized name: LOCAL ANESTHETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetics (3.6 ml submucous injection)
Study: 30664012
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% levobupivacaine (5 ml/h)
Study: 30664012
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus infusion of 0.2% levobupivacaine (15 ml every 3h)
Study: 30664012
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus infusion of 0.2% levobupivacaine
Study: 30664012
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% levobupivacaine
Study: 25932549
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab 0.16 mg/0.05 mL
Study: 23798671
Drug: Rifaximin 25
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 25 mg once daily for 5 days
Study: 17023279
Drug: Preoperative multiple-injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative multiple-injection thoracic paravertebral blocks (PVB group, n = 25)
Study: 17023279
Drug: Preoperative multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative multiple subcutaneous saline injections (Control group, n = 25)
Study: 9337499
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (voucher incentive program and community reinforcement approach)
Study: 9337499
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (lifestyle counseling)
Study: 3527305
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 1.000 mg/day with hydrocortisone (HC) 20‐40 mg/day
Study: 24906582
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus yoga
Study: 21833588
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of 75 mg/m² cisplatin plus 75 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm A)
Study: 21833588
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of 25 mg/m² cisplatin plus 25 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm B)
Study: 17466852
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 4 times daily for 3 days preoperatively and 1 month postoperatively
Study: 17466852
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 4 times daily for 1 month postoperatively
Study: 17466852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only topical steroids and antibiotics
Study: 17466852
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin preoperatively
Study: 17466852
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin postoperatively
Study: 16326294
Drug: Topical valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical valdecoxib
Study: 12176795
Drug: RPR 109881A
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 109881A (1-hour infusion)
Study: 12176795
Drug: RPR 109881A
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 109881A (3-hour infusion)
Study: 9447850
Drug: Atenolol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (0, 5, or 10 mg intravenously before induction of anesthesia and every 12 h after operation until the patient could take oral medications; 0, 50, or 100 mg orally once a day as specified by blood pressure and heart rate)
Study: 776538
Drug: Lysometra (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysometra (2.5 ml intramuscular injections for three 20-day courses)
Study: 776538
Drug: Methylandrostendiol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylandrostendiol (5 mg intramuscular injections for three 20-day courses)
Study: 31050109
Drug: iGlarLixi 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi 5 U/5 μg
Study: 31050109
Drug: iGlarLixi 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi 10 U/10 μg
Study: 31050109
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 5 U
Study: 25408222
Drug: Macushield (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macushield (10 mg meso‐zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Study: 23338109
Drug: Lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 3 mg/kg with Nitroglycerin 200 µg
Study: 16446342
Drug: Vinorelbine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine and cisplatin alone (placebo patch, arm B)
Study: 9466165
Drug: RS-8359 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359 (multiple doses)
Study: 9466165
Drug: RS-8359 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359 (single dose)
Study: 8187308
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lanreotide (SR-L)
Study: 8187308
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with SR-L (2-3 injections/month for 3-6 months)
Study: 2856773
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg once daily
Study: 3034318
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + HCTZ 25 mg once daily
Study: 3034318
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg + Captopril 50 mg once daily
Study: 19819530
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg and standard analgesia (tylenol with codeine)
Study: 15947595
Drug: Screening arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screening arm (Prostate specific antigen testing, digital rectal examination, transrectal ultrasound, sextant biopsies)
Study: 14638545
Drug: Renal insufficiency
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal insufficiency (CrCl ≤60 mL/min)
Study: 11409184
Drug: Oral doxofylline
Normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxofylline (400 mg BID)
Study: 1899136
Drug: Levonorgestrel IUD
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel IUD (20 micrograms daily)
Study: 26330052
Drug: High-potency topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency topical agents
Study: 26330052
Drug: Regional differences
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional differences in topical use
Study: 22192731
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus erlotinib (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2, erlotinib 100 mg daily)
Study: 22192731
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2)
Study: 22192731
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus erlotinib (for cholangiocarcinoma subgroup)
Study: 22192731
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (for cholangiocarcinoma subgroup)
Study: 16358997
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rofecoxib combined with simvastatin
Study: 16310019
Drug: BWLP+SC [PST]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BWLP+SC [PST] (behavioral weight loss program with stepped-care approach including problem-solving therapy)
Study: 1992599
Drug: Nilutamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilutamide (300 mg/day) plus buserelin
Study: 6357890
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg intramuscular diclofenac sodium (Voltaren)
Study: 30203750
Drug: Celecoxib therapy
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib therapy
Study: 30203750
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium therapy
Study: 25246338
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of donor adipose-derived mesenchymal stem cells (AD-MSC) + hematopoietic stem cells (HSC)